Karen Hong, Ph.D.

Partner at Novo Ventures, Co-Founder

Dr. Hong brings over 25 years of experience in life science investing and biomedical research. Dr. Hong is a Partner with the Ventures Investment team at Novo Holdings.  Prior to joining Novo Holdings, Dr. Hong was a Senior Investment Director at Takeda Ventures, Inc. and was a Partner at ProQuest Investments. She currently serves on the Board of Directors of StrideBio and Riva Therapeutics, which she incubated, co-founded, and launched in collaboration with the Broad Institute.  Additional boards where she has been a Director or Observer include Obsidian Therapeutics, Palleon Pharmaceuticals, Agile Therapeutics, BioRexis Pharmaceutical Corp. (acquired by Pfizer), Gloucester Pharmaceuticals (acquired by Celgene) and LEAD Therapeutics (acquired by BioMarin), among others. Prior to joining ProQuest, Dr. Hong led numerous research projects in the area of mammalian cancer genetics and genomics in the laboratory of Dr. Eric Lander at the Whitehead Institute for Biomedical Research.

Dr. Hong received a Ph.D. in biology from the Massachusetts Institute of Technology and holds a B.S. in chemistry and a B.A. in molecular biology from the University of California at Berkeley, where she graduated with honors.